Business
PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference
BOSTON, Sept. 01, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide
About this update from Pepgen Inc.
[{"type":"text","content":"BOSTON, Sept. 01, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it will be presenting at upcoming medical meetings and an investor conference. Ashling Holland, Director of Preclinical Development at PepGen, will be giving a talk titled “PGN-EDODM1 nonclinical data demonstrated mechanistic and meaningful activity for the potential treatment of myotonic dystrophy type 1 (DM1)”, at the 2023 Myotonic Dystrophy Foundation Annual Conference, on September 9, 2023, in Washington, D.C. PepGen will also be making three poster presentations at the 2023 Ottawa Neuromuscular Disease Meeting, being held September 7-9, 2023, in Ottawa, ON, Canada. In addition, James McArthur, Ph.D., President and CEO of PepGen will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11th at 10:30am ET being held in New York. The corporate presentation made at the H.C. Wainwright conference will be webcast live on the Events & Presentations section of the Investor Relations section of PepGen’s website. A replay of the event will be archived for 90 days. MDF Presentation: Title: PGN-EDODM1 Nonclinical data demonstrated mechanistic and meaningful activity for the potential treatment of myotonic dystrophy type 1 (DM1)Session: Industry Updates Part 2 Location: Potomac Ballroom Date & Time: September 9th at 2:45-3:45pm EDTPresenter: Ashling Holland, Ph.D., Director of Preclinical Development Ottawa NMD Poster Presentations: Title: FREEDOM-DM1: Nonclinical data support the Phase 1 study design to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of PGN-EDODM1 in adults with myotonic dystrophy Type 1 (DM1)Poster Number: Poster #73Date & Time: September 8th at 3:00-4:00pm EDTPresenter: Michelle Mellion, MD, Senior Vice President, Head of Clinical Development Title: CONNECT-EDO51: Nonclinical and Phase 1 Data Support Phase 2 Trial Designs to Continue Evaluating Safety and Efficacy of PGN-EDO51 for Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 SkippingPoster Number: Poster #75Date & Time: September 8th at 3:00-4:00pm EDTPresenter: Michelle Mellion, MD, Senior Vice President, Head of Clini...